ARQL News and Press, ArQule Inc. From 06/17/19

Gainers: MGI   +117.9% . PHAS   +14.0% . NSPR   +7.4% . EIGR   +4.9% . ARQL   +2.7% . More news on: MoneyGram International, Inc., PhaseBio Pharmaceuticals, Inc., InspireMD, Inc., Stocks on the move, , News on ETFs Read more ...

Encouraging preliminary safety and clinical activity data confirm miransertib’s potential for treating PS and PROS patients Registrational study, MOSAIC (Miransertib in Overgrowth Syndromes in Adults and Children), expected to begin enrollment in Q3 2019 ArQule, Inc. (N...

ARQL stock is having an impressive run on the market today after ArQule, Inc. (NASDAQ:ARQL) announced encouraging data from the Phase 1 trial of ARQ 531, its investigational cancer product. About Today’s Development In this regard, it needs to be pointed out that the product...

Gainers: Bluegreen Vacations (NYSE: BXG ) +35% . ArQule (NASDAQ: ARQL ) +34% . Avadel Pharmaceuticals (NASDAQ: AVDL ) +20% . Moxian (NASDAQ: MOXC ) +17% . Outlook Therapeutics (NASDAQ: OTLK ) +17% . BBX Capital (NYSE: BBX ) +15% . Puyi (NASDAQ: PUYI ) +11% . MYOS RENS Technolo...

ArQule (NASDAQ: ARQL ) +35.9% pre-market after releasing preliminary results from its phase 1 dose escalation study for ARQ 531 demonstrates substantial anti-tumor activity and a favorable safety profile. More news on: ArQule, Inc., Healthcare stocks news, Stocks on the move, Read ...

-ARQ 531 demonstrates substantial anti-tumor activity and favorable safety profile -Four of six evaluable CLL patients, all with the BTK-C481S mutation, from cohort 7 (65 mg) experienced a Partial Response -Partial Response also observed in the study’s first Richter’...

Presentation highlights preliminary results from phase 1/2 study of miransertib in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) ArQule, Inc. (Nasdaq:ARQL), today announced it will present preliminary results from the company’s phase 1/2 stud...

Noteworthy events during the week of June 9 - 15 for healthcare investors. More news on: Merck & Co., Inc., Xeris Pharmaceuticals, Inc., Mallinckrodt plc, Healthcare stocks news, , Read more ...

Presentation highlights phase 1 dose escalation study in patients with relapsed or refractory B-cell lymphoid malignancies Conference call and webcast with ArQule management and Dr. Jennifer Woyach, Principal Investigator, to be held Friday, June 14, 2018 at 8:00 a.m. EDT ArQule M...

SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie...